0:02
Hello, my name is Dr. Philip Me and I'm here at ACR Convergence 2026 and I'd like to tell you about abstract 347, which is on the UPSTAND study.
0:17
The UPSTAND study is a study of the use of upadacitinib for the treatment of axial spondyloarthritis conducted in Europe, over 600 patients.
0:32
The unique part of this study is that it included measures of not only neuropathic pain but also nociplastic pain, meaning it was able to tell about the presence of conditions like fibromyalgia that were present in patients in this study.
0:54
Even though fibromyalgia was an exclusion from the inclusion and exclusion criteria, it turned out that 49% of the patients scored high on the WPI, widespread pain index, and SSS, symptom severity score.
1:14
This constitutes the fibromyalgia classification measurement criteria developed by Fred Wolfe and published in 2016, and is a good measure of the presence of nociplastic pain or central sensitization pain in patients, which we know is a big issue.
1:37
So even though the patients with overt fibromyalgia were excluded, 49% scored high on this measure.
1:46
We got to determine what happened to them during the trial.
1:50
As anticipated, those patients that scored high had some blunting of pain response with the treatment of upadacitinib, which otherwise in patients without nociplastic pain scored really high benefits for pain occurring really rapidly.
2:09
So there was some blunting of course, and we were of course disappointed by that.
2:15
But then what was very interesting was that the primary endpoint in the trial several weeks later showed that the WPI and SSS scores went down, suggesting that it was having some impact on central pain.
2:34
At this meeting, there was a further analysis which showed that when pain improved as soon as one week into the course of the study,
2:46
there were significant benefits to the patients who had had such a rapid improvement, including benefits for composite scores like the ASDAS, as well as
2:59
benefits on physical function, quality of life, and also likelihood of reduction in the widespread pain index down the road.
3:09
So we're learning that upadacitinib as a JAK inhibitor can have a rapid significant benefit for pain and potentially modulate the central sensitization type of pain that is present in many of our rheumatic disease patients.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.